Glatiramer acetate: A complex drug beyond biologics

Area of Science:

• Pharmaceutical Sciences
• Regulatory Affairs
• Drug Development

Background:

• Non-Biological Complex Drugs (NBCDs) quality is highly dependent on manufacturing processes.
• Complexity in NBCDs can stem from the active substance (e.g., glatiramer acetate) or formulation (e.g., liposomes).
• Glatiramer acetate (GA) is a clinically and economically significant NBCD.

Purpose of the Study:

• To analyze the regulatory pathways for glatiramer acetate (GA) marketing authorization in the US and EU.
• To highlight the differences in regulatory implementation between the two jurisdictions.
• To compare the US and EU approaches to approving generic versions of complex drugs.

Main Methods:

• Comparative analysis of US and EU regulatory guidelines for glatiramer acetate.
• Review of marketing authorization processes and data requirements.
• Examination of policies regarding interchangeability and substitution.

Main Results:

• The US employs a generic approach with a product-specific guideline, leading to approved generic glatiramer acetate (Copaxone® copies).
• The EU utilizes a hybrid approach, mandating an additional comparative study for marketing authorization.
• Interchangeability and substitution policies for GA are managed at the national level in the EU.

Conclusions:

• Significant divergence exists in US and EU regulatory strategies for Non-Biological Complex Drugs (NBCDs) like glatiramer acetate.
• The US approach facilitates generic approvals more directly than the EU's comparative study requirement.
• Harmonization of regulatory frameworks for complex drugs remains a challenge.